Immune Cell Clusters in Kidneys Linked to Faster Diabetic Kidney Disease Progression
A new study from the Perelman School of Medicine at the University of Pennsylvania has identified a distinct form of diabetic kidney disease (DKD) characterized by clusters of B immune cells within the kidney tissue. This form of DKD is associated with a more rapid progression to kidney failure, offering potential for more targeted treatments, according to research published today in Nature.
Understanding Diabetic Kidney Disease
Diabetic kidney disease affects a significant portion of individuals with diabetes, ranging from 20 to 40 percent. It is a leading cause of both chronic kidney disease (CKD) and end-stage kidney disease (ESKD). In the United States, approximately one in three adults with diabetes also has CKD. Globally, the prevalence of chronic type 2 DKD has risen substantially, increasing by 85 percent since 1990 to over 107 million people in 2021, driven by factors such as population growth, aging, and increased diabetes survival rates.
The Role of Immune Cells
Traditionally, DKD has been viewed as a single condition. However, this research suggests a more nuanced picture. By examining kidney tissue at a single-cell resolution, researchers identified a subset of patients with DKD who exhibit prominent clusters of B cells within their kidneys. These B cell clusters appear to correlate with a faster decline in kidney function.
How the Study Was Conducted
The researchers utilized a novel technology that allows for the study of gene activity within tissue samples whereas preserving the tissue’s structural integrity. This approach enabled them to map the kidney tissue in detail and identify the unique characteristics of this high-risk form of DKD. The study is part of the Transformative Research in Diabetic Nephropathy (TRIDENT) initiative, a public-private partnership focused on developing new DKD therapeutics. TRIDENT integrates kidney biopsy pathology, multi-omic profiling, and longitudinal clinical outcomes to improve diagnostics and treatments.
Implications for Treatment
Currently, doctors assess CKD progression using measures like kidney function and protein levels in urine. However, these indicators don’t fully explain the variability in disease progression among patients. The identification of this B cell-associated form of DKD opens the door for more personalized treatment strategies. By identifying the specific disease processes occurring in each patient’s kidney, clinicians may be able to tailor treatments for improved outcomes.
Future Directions
The research team plans to continue investigating the mechanisms driving B cell accumulation in the kidneys of DKD patients. Further studies will focus on identifying potential therapeutic targets to modulate the immune response and slow disease progression. The TRIDENT consortium will continue to follow patients over time to validate these findings and translate them into clinical practice.